Differential regulation of breast cancer bone metastasis by PARP1 and PARP2

PARP1 and PARP2 dual inhibitors, such as olaparib, have been recently FDA approved for the treatment of advanced breast and ovarian cancers. However, their effects on bone mass and bone metastasis are unknown. Here we show that olaparib increases breast cancer bone metastasis through PARP2, but not...

Descripción completa

Detalles Bibliográficos
Autores principales: Zuo, Hao, Yang, Dengbao, Yang, Qiwen, Tang, Haidong, Fu, Yang-Xin, Wan, Yihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101362/
https://www.ncbi.nlm.nih.gov/pubmed/32221289
http://dx.doi.org/10.1038/s41467-020-15429-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101362/
https://www.ncbi.nlm.nih.gov/pubmed/32221289
http://dx.doi.org/10.1038/s41467-020-15429-z

Ejemplares similares